Pathogenesis and immune mechanisms of chronic Inflammatory Bowel Diseases

American Journal of Gastroenterology

Volumn 92, Issue 12 SUPPL., 1997, Pages

  Sartor, R Balfour ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROHN DISEASE; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; INTESTINE INFECTION; INTESTINE MUCOSA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

CHRONIC DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 0030830553     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995;24:475-507.
2. Wakefield AJ, Ekbom A, Dhillon AP, et al. Crohn's disease: Pathogenesis and persistent measles virus infection. Gastroenterology 1995; 108:911-6.
3. Liu Y van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995;108:1396-404.
4. Sanderson JD, Moss MT, Tizard MLV, et al. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut 1992;33:890-6.
5. Sartor RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins, 1995:96-124.
6. Roediger WEW, Duncan A, Kapaniris O, et al. Reducing sulfur compounds of the colon impair colonocyte nutrition: Implications for ulcerative colitis. Gastroenterology 1993;104:802-9.
7. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993;104:1627-32.
8. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996;110:1395-403.
9. Podolsky DK, Isselbacher KJ. Glycoprotein composition of colonic mucosa: specific alterations in ulcerative colitis. Gastroenterology 1984;87:991-8.
10. Rhodes JM. Colonic mucus and mucosal glycoproteins: The key to colitis and cancer? Gut 1989;30:1660-6.
11. Clamp JR, Fraser G, Read AE. Study of the carbohydrate content of mucus glycoproteins from normal and diseased colons. Clin Sci 1981; 61:229-34.
12. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270:1203-7.
13. Mashimo H, Wu DC, Podolsky DK, et al. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996; 274:262-5.
14. 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-4.
15. Kühn R, Löhler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
16. Mombaerts P, Mizoguchi E, Grusby MJ, et al. Spontaneous development of inflammatory bowel disease in T-cell receptor mutant mice. Cell 1993;75:275-82.
17. Casini-Raggi V, Kam L, Chong YJT, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: A novel mechanism of chronic intestinal inflammation. J Immunol 1995;154: 2434-40.
18. Schreiber S, Heinig T, Panzer U, et al. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995;108:21-33.
19. Shanahan F. Current concepts of the pathogenesis of inflammatory bowel disease. Ir J Med Sci 1994;163:544-9.
20. Shanahan F, Duerr RH, Rotter JI, et al. Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. Gastroenterology 1992;103:456-61.
21. Lee JC, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology 1995;108:428-33.
22. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994;107:103-8.
23. Satsangi J, Jewell DP, Rosenberg WMC, et al. Genetics of inflammatory bowel disease. Gut 1994;35:696-700.
24. Elson CO, Sartor RB, Tennyson G, et al. Experimental models of IBD. Gastroenterology 1995;109:1344-67.
25. Sachar DB. Crohn's disease: A family affair. Gastroenterology 1996; 111:813-5.
26. Bayless TM, Tokayer AZ, Polito JM II, et al. Crohn's disease: Concordance for site and clinical type in affected family members: Potential hereditary influences. Gastroenterology 1996;111:573-9.
27. Colombel JF, Grandbastien B, Gower-Rousseau C, et al. Clinical characteristics of Crohn's disease in 72 families. Gastroenterology 1996;111:604-7.
28. Polito JM II, Rees RC, Childs B, et al. Preliminary evidence for genetic anticipation in Crohn's disease. Lancet 1996;347:798-800.
29. Toyoda H, Wang SJ, Yang HY, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
30. Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-7.
31. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-42.
32. Plevy SE, Targan SR, Yang H, et al. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996;110:1053-60.
33. Yang H, Vora DK, Targan SR, et al. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology 1995;109:440-8.
34. F gene in Crohn's disease. Acta Med Scand 1984;215:375-8.
35. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996;14:199-202.
36. Hugot J-P, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3.
37. Sartor RB, DeLa Cadena RA, Green KD, et al. Selective kallikreinkinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 1996;110:1467-81.
38. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98: 1010-20.
39. 2 microglobulin transgenic rats. J Clin Invest 1996;98:945-53.
40. Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:364-71.
41. Koutroubakis I, Manousos ON, Meuwissen SG, et al. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996;43:381-93.
42. Powell SJ, Wilmot AJ. Ulcerative post-dysenteric colitis. Gut 1966;7: 438-43.
43. Bjarnason I, Macpherson A, Somaslindaram S, et al. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease. Can J Gastroenterol 1993;7:160-9.
44. Sartor RB, Lichtman SN. Mechanisms of systemic inflammation associated with intestinal injury. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: From bench to bedside. Baltimore: Williams & Wilkins, 1994:210-29.
45. Sartor RB. Treating IBD by altering luminal contents, rationale and response. In: Rachmilewitz D, ed. Inflammatory bowel diseases. Dordrecht: Kluwer Academic Publishers, 1994:177-91.
46. Madsen KL, Tavernini MM, Doyle JSG, et al. Lactobacillus sp. prevents development of enterocolitis in interleukin-10 gene deficient mice. Gastroenterology 1997;112:A1030.
47. MacDermott RP. Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am 1884;78:1207-31.
48. Jewell DP. Immunology of inflammatory bowel disease: An update. J Gastroenterol 1995;8:78-82.
49. Sartor RB. Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology 1994;106:533-9.
50. Sartor RB. Cytokine regulation of experimental intestinal inflammation in genetically engineered and T-lymphocyte reconstituted rodents. Aliment Pharmacol Ther 1996;2:36-42.
51. Powrie F. T cells in inflammatory bowel disease: Protective and pathogenic roles. Immunity 1995;3:171-4.
52. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
53. Breese E, Braegger CP, Corrigan CJ, et al. Interleukin-2- and interferon-γ-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993;78:127-31.
54. Mullin GE, Lazenby AJ, Harris ML, et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992;102:1620-7.
55. Mullin GE, Maycon ZR, Braun-Elwert L, et al. Inflammatory bowel disease mucosal biopsies have specialized lymphokine mRNA profiles. Inflammatory Bowel Dis 1996;2:16-26.
56. Gilberts EC, Greenstein AJ, Katsel P, et al. Molecular evidence for two forms of Crohn's disease. Proc Natl Acad Sci USA 1994;91:12721-4.
57. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990;86:1255-60.
58. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
59. Madara JL, Stafford J. Interferon-γ directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 1989;83:724-7.
60. Colgan SP, Parkos CA, Delp C, et al. Neutrophil migration across cultured intestinal epithelial monolayers is modulated by epithelial exposure to IFN-γ in a highly polarized fashion. J Cell Biol 1993;120: 785-98.
61. MacDonald TT, Spencer J. Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine. J Exp Med 1988;167:1341-9.
62. Conner EM, Brand SJ, Davis JM, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: Toxins, mediators, and modulators of gene expression. Inflammatory Bowel Dis 1996;2:133-47.
63. Strong SA, West GA, Klein JS, et al. Inflammatory cytokines stimulate proliferation of intestinal mucosa mesenchymal cells. Gastroenterology 1992;102:A701.
64. Zimmermann EM, Sartor RB, McCall RD, et al. Insulinlike growth factor I and interleukin 1 beta messenger RNA in a rat model of granulomatous enterocolitis and hepatitis. Gastroenterology 1993;105: 399-409.
65. Stallmach A, Schuppan D, Riese HH, et al. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology 1992;102:1920-9.
66. Roberts WG, Simon TJ, Berlin RG, et al. Leukotrienes in ulcerative colitis: Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997;112:725-32.
67. Targan SR, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
68. Van Deventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease: Crohn's Disease Study Group. Gastroenterology 1997;113:383-9.
69. Plevy SE, Taylor K, DeWoody KL, et al. Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody identify Crohn's disease (CD) patients with poor clinical responses to anti-TNF monoclonal antibody (cA2). Gastroenterology 1997;112:A1062.